CN106176748B - 去甲异波尔定在制备抗抑郁症药物中的用途 - Google Patents
去甲异波尔定在制备抗抑郁症药物中的用途 Download PDFInfo
- Publication number
- CN106176748B CN106176748B CN201610695266.1A CN201610695266A CN106176748B CN 106176748 B CN106176748 B CN 106176748B CN 201610695266 A CN201610695266 A CN 201610695266A CN 106176748 B CN106176748 B CN 106176748B
- Authority
- CN
- China
- Prior art keywords
- norisoboldine
- drug
- depression
- antidepressant
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HORZNQYQXBFWNZ-LBPRGKRZSA-N (6as)-2,10-dimethoxy-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1,9-diol Chemical compound N1CCC2=CC(OC)=C(O)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 HORZNQYQXBFWNZ-LBPRGKRZSA-N 0.000 title claims abstract description 157
- HORZNQYQXBFWNZ-UHFFFAOYSA-N dl-Norisoboldin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=C3C=C(OC)C(O)=C1 HORZNQYQXBFWNZ-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 239000000935 antidepressant agent Substances 0.000 title claims abstract description 41
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 230000037396 body weight Effects 0.000 claims abstract description 10
- 239000007924 injection Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- LINHZVMHXABQLB-ZDUSSCGKSA-N Isoboldine Chemical compound CN1CCC2=CC(OC)=C(O)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LINHZVMHXABQLB-ZDUSSCGKSA-N 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 10
- PLEOQAHCVRVCDL-UHFFFAOYSA-N 2,9-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,10-diol Natural products CN1CCC2=CC(OC)=C(O)C3=C2C1CC1=C3C=C(O)C(OC)=C1 PLEOQAHCVRVCDL-UHFFFAOYSA-N 0.000 claims description 7
- CRSMCADHSFQBLA-UHFFFAOYSA-N isoboldine Natural products COc1cc-2c(CC3N(C)CCc4cccc-2c34)cc1O CRSMCADHSFQBLA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 21
- 229960004801 imipramine Drugs 0.000 abstract description 18
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 abstract description 18
- 229940005513 antidepressants Drugs 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 241001465754 Metazoa Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 238000012048 forced swim test Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 4
- 229960002102 imipramine hydrochloride Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 235000008671 Calycanthus floridus Nutrition 0.000 description 3
- 235000008670 Calycanthus occidentalis Nutrition 0.000 description 3
- 206010054089 Depressive symptom Diseases 0.000 description 3
- 244000148992 Lindera benzoin Species 0.000 description 3
- 235000004520 Lindera benzoin Nutrition 0.000 description 3
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KYVJVURXKAZJRK-UHFFFAOYSA-N (+)-laurolitsine Natural products N1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 KYVJVURXKAZJRK-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 241000546273 Lindera <angiosperm> Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- MHVCSDLBQKSFQV-HNNXBMFYSA-N boldine Natural products COc1cc2c(C[C@@H]3N(C)CCc4cc(C)c(OC)c2c34)cc1O MHVCSDLBQKSFQV-HNNXBMFYSA-N 0.000 description 1
- LZJRNLRASBVRRX-UHFFFAOYSA-N boldine trifluoroacetic acid salt Natural products CN1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Abstract
Description
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510671062 | 2015-10-16 | ||
CN201510671062X | 2015-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106176748A CN106176748A (zh) | 2016-12-07 |
CN106176748B true CN106176748B (zh) | 2019-01-18 |
Family
ID=56394169
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610158023.4A Pending CN105770357A (zh) | 2015-10-16 | 2016-03-18 | 蒜氨酸在制备抗抑郁症药物中的用途 |
CN201610158225.9A Active CN105832724B (zh) | 2015-10-16 | 2016-03-18 | 吲哚醇在制备抗抑郁症药物中的用途 |
CN201610494641.6A Active CN106038522B (zh) | 2015-10-16 | 2016-06-28 | 大黄酸在制备抗抑郁症药物中的用途 |
CN201610695266.1A Active CN106176748B (zh) | 2015-10-16 | 2016-08-19 | 去甲异波尔定在制备抗抑郁症药物中的用途 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610158023.4A Pending CN105770357A (zh) | 2015-10-16 | 2016-03-18 | 蒜氨酸在制备抗抑郁症药物中的用途 |
CN201610158225.9A Active CN105832724B (zh) | 2015-10-16 | 2016-03-18 | 吲哚醇在制备抗抑郁症药物中的用途 |
CN201610494641.6A Active CN106038522B (zh) | 2015-10-16 | 2016-06-28 | 大黄酸在制备抗抑郁症药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN105770357A (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110251559A (zh) * | 2019-07-29 | 2019-09-20 | 西南交通大学 | 一种乌药块茎提取物在制备抗抑郁药物中的应用 |
CN112168968A (zh) * | 2020-09-25 | 2021-01-05 | 中山大学附属第八医院(深圳福田) | Fto抑制剂在制备防治乳腺癌产品中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1762359A (zh) * | 2005-09-28 | 2006-04-26 | 上海中医药大学 | 乌药生物碱及其制备方法与在制药中的应用 |
CN101375850A (zh) * | 2008-10-07 | 2009-03-04 | 中国药科大学 | 去甲异波尔定在制备治疗自身免疫性疾病药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5962566A (ja) * | 1982-10-01 | 1984-04-10 | Tanabe Seiyaku Co Ltd | ヒドロキシインド−ルの製法 |
US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
DE10253426B4 (de) * | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
CN1440747A (zh) * | 2003-03-31 | 2003-09-10 | 中国人民解放军肾脏病研究所 | 大黄酸或大黄酸盐在制备治疗肥胖症药物中的应用 |
CN1269527C (zh) * | 2003-06-03 | 2006-08-16 | 陈坚 | 复方蒜氨酸粉针剂 |
FR2918570B1 (fr) * | 2007-07-09 | 2012-10-05 | Engelhard Lyon | DIGLYCATION DES AGEs. |
CN101327289B (zh) * | 2008-07-31 | 2011-06-15 | 倪健 | 黄花菜及黄花菜总黄酮的新用途 |
CN102060809B (zh) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种大黄酸衍生物及其制备和用途 |
-
2016
- 2016-03-18 CN CN201610158023.4A patent/CN105770357A/zh active Pending
- 2016-03-18 CN CN201610158225.9A patent/CN105832724B/zh active Active
- 2016-06-28 CN CN201610494641.6A patent/CN106038522B/zh active Active
- 2016-08-19 CN CN201610695266.1A patent/CN106176748B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1762359A (zh) * | 2005-09-28 | 2006-04-26 | 上海中医药大学 | 乌药生物碱及其制备方法与在制药中的应用 |
CN101375850A (zh) * | 2008-10-07 | 2009-03-04 | 中国药科大学 | 去甲异波尔定在制备治疗自身免疫性疾病药物中的应用 |
Non-Patent Citations (3)
Title |
---|
"Norisoboldine attenuates inflammatory pain via the adenosine A1 receptor;X. Gao 等;《European Journal of Pain》;20140831;第18卷(第7期);第939-948页 |
Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a;Tsvetan Serchov 等;《Neuron》;20150805;第87卷(第3期);第549-562页 |
Norisoboldine attenuates inflammatory pain via the adenosine A1 receptor;X. Gao 等;《European Journal of Pain》;20140831;第18卷(第7期);第939-948页 |
Also Published As
Publication number | Publication date |
---|---|
CN105770357A (zh) | 2016-07-20 |
CN106038522B (zh) | 2019-08-16 |
CN106038522A (zh) | 2016-10-26 |
CN105832724A (zh) | 2016-08-10 |
CN106176748A (zh) | 2016-12-07 |
CN105832724B (zh) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102274227B (zh) | 粉防己碱在制备预防和/或治疗抑郁症药物中的应用 | |
CN107951869A (zh) | 含有大麻二酚的药物制剂及其应用 | |
CN103432184B (zh) | 牛蒡子提取物在制药或食品中的应用 | |
CN106176748B (zh) | 去甲异波尔定在制备抗抑郁症药物中的用途 | |
CN106038534B (zh) | 冬凌草甲素在制备抗抑郁症药物中的用途 | |
CN103202894B (zh) | 一种预防和治疗鸭传染性浆膜炎的中草药饲料添加剂 | |
CN104223073B (zh) | 一种助眠的食品、保健品或药物组合物 | |
CN105030799A (zh) | 二苯乙烯苷在制备镇痛药物中的应用 | |
CN106265713B (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
CN105777520A (zh) | 一种新型查尔酮化合物Chalcone-1203及其组合物、制备方法和应用 | |
CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
JP7090731B2 (ja) | 柿葉抽出物及びその製剤の新規医薬用途 | |
CN1137702C (zh) | 中草药大叶蒟乙酸乙酯抽提物在制备精神类药物中的应用 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN101450063A (zh) | 治疗忧郁症的口服药物 | |
CN105816460B (zh) | 一种治疗产后抑郁的药物组合物 | |
CN104211645B (zh) | 嘧啶类衍生物及其应用 | |
CN107281183B (zh) | 一种镇痛药物组合物 | |
CN102462696B (zh) | 乌骨鸡黑色素提取物在制备防治抑郁症的药物中的用途 | |
CN101584768B (zh) | 一种治疗痔疮的熏洗液及其制造方法 | |
KR20210135834A (ko) | 헤스페리딘을 유효성분으로 함유하는 외상 후 스트레스장애 예방 또는 치료용 조성물 | |
CN104606217A (zh) | 梓醇在制备抗抑郁药物中的应用 | |
KR20210135835A (ko) | 움벨리페론을 유효성분으로 함유하는 외상 후 스트레스장애 예방 또는 치료용 조성물 | |
RU2182012C1 (ru) | Способ применения антипаразитарной настойки | |
CN104257658B (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220608 Address after: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee after: Luo Yongqiang Address before: Room b273, Chuangxin building, No. 29, shengshengyuan Road, Changping District, Beijing 102206 Patentee before: BEIJING GRAGEN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: Floor 3, Building 402, Zone 1, Tiantong Dongyuan, Dongxiaokou Town, Changping District, Beijing, 102218 Patentee after: Beijing Yasheng Bohou Biotechnology Development Center Address before: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee before: Luo Yongqiang |